FibroGen, Inc. (FGEN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1154135,
    "name": "FibroGen, Inc.",
    "stock_name": "FibroGen, Inc.",
    "full_name": "FibroGen, Inc.",
    "name_url": "stocks-analysis/fibrogen-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "8.25",
    "chg": 0.17,
    "chgp": "2.1%",
    "dir": 1,
    "prev_price": "8.08",
    "mcapval": "45.13",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US31572Q8087",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "49.92 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/fibrogen-inc-1154135-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "FibroGen Stock Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/fibrogen-stock-forms-golden-cross-signaling-potential-bullish-breakout-3559457",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/FibroGenInc_goldencross_3559457.png",
        "date": "2025-09-23 15:41:57",
        "description": "FibroGen, Inc. has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock has shown notable daily activity, outperforming the S&P 500. Technical indicators reflect a bullish stance, suggesting a possible turnaround despite a challenging longer-term performance."
      },
      {
        "title": "Is FibroGen, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-fibrogen-inc-technically-bullish-or-bearish-3546490",
        "imagepath": "",
        "date": "2025-09-20 19:34:08",
        "description": "As of 8 August 2025, the technical trend for FibroGen, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish and the KST is also bullish, indicating positive momentum. However, the daily moving averages are mildly bearish, which suggests some short-term weakness. The Bollinger Bands show a mildly bullish stance on the weekly but bearish on the monthly, indicating mixed signals. The stock has underperformed against the S&P 500 over the year, with a return of 8.38% compared to the S&P's 17.14%. Overall, the technical stance is bullish, but caution is warranted due to mixed signals in shorter time frames...."
      },
      {
        "title": "Is FibroGen, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-fibrogen-inc-overvalued-or-undervalued-3543062",
        "imagepath": "",
        "date": "2025-09-20 18:09:38",
        "description": "As of 2 March 2020, the valuation grade for FibroGen, Inc. moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued given its negative valuation ratios, including an EV to EBITDA of -3.19 and a Price to Book Value of -0.15. Additionally, its P/E ratio is not applicable due to the company being loss-making, further underscoring its financial challenges.\n\nIn comparison to peers, FibroGen's valuation ratios are significantly worse, with Chimerix, Inc. showing a P/E of -8.6897 and EV to EBITDA of -6.6011, while CytomX Therapeutics, Inc. stands out with a very attractive P/E of 7.4924. FibroGen's stock has underperformed against the S&P 500, with a year-to-date return of -14.03% compared to the index's 12.22%, reinforcing the notion that the company is currently overvalued...."
      }
    ],
    "total": 8,
    "sid": "1154135",
    "stock_news_url": "https://www.marketsmojo.com/news/fibrogen-inc-1154135"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

FibroGen Stock Forms Golden Cross, Signaling Potential Bullish Breakout

2025-09-23 15:41:57

FibroGen, Inc. has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock has shown notable daily activity, outperforming the S&P 500. Technical indicators reflect a bullish stance, suggesting a possible turnaround despite a challenging longer-term performance.

Is FibroGen, Inc. technically bullish or bearish?

2025-09-20 19:34:08

As of 8 August 2025, the technical trend for FibroGen, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish and the KST is also bullish, indicating positive momentum. However, the daily moving averages are mildly bearish, which suggests some short-term weakness. The Bollinger Bands show a mildly bullish stance on the weekly but bearish on the monthly, indicating mixed signals. The stock has underperformed against the S&P 500 over the year, with a return of 8.38% compared to the S&P's 17.14%. Overall, the technical stance is bullish, but caution is warranted due to mixed signals in shorter time frames....

Is FibroGen, Inc. overvalued or undervalued?

2025-09-20 18:09:38

As of 2 March 2020, the valuation grade for FibroGen, Inc. moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued given its negative valuation ratios, including an EV to EBITDA of -3.19 and a Price to Book Value of -0.15. Additionally, its P/E ratio is not applicable due to the company being loss-making, further underscoring its financial challenges. In comparison to peers, FibroGen's valuation ratios are significantly worse, with Chimerix, Inc. showing a P/E of -8.6897 and EV to EBITDA of -6.6011, while CytomX Therapeutics, Inc. stands out with a very attractive P/E of 7.4924. FibroGen's stock has underperformed against the S&P 500, with a year-to-date return of -14.03% compared to the index's 12.22%, reinforcing the notion that the company is currently overvalued....

View All News